Last Updated : July 24, 2024
Details
Generic Name:
mepolizumab
Project Status:
Not filed
Therapeutic Area:
Asthma, severe eosinophilic (pediatric)
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Nucala
Project Line:
Reimbursement Review
Project Number:
NS0027-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Adolescents and children (aged 6 years and older) who are inadequately controlled with medium-to-high-dose inhaled corticosteroids and an additional asthma controller (e.g., LABA); and who have a blood eosinophil count of ? 150 cells/mcL (0.15 GI/L) at initiation of treatment with Nucala OR ? 300 cells/mcL (0.3 GI/L) in the past 12 months.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024